Cargando…

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction

The Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant formulated in a stable emulsion (GLA-SE) promotes strong T(H)1 and balanced IgG1/IgG2 responses to protein vaccine antigens. This enhanced immunity is sufficient to provide protection against many diseases including tuberculosis and leis...

Descripción completa

Detalles Bibliográficos
Autores principales: Cauwelaert, Natasha Dubois, Desbien, Anthony L., Hudson, Thomas E., Pine, Samuel O., Reed, Steven G., Coler, Rhea N., Orr, Mark T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701231/
https://www.ncbi.nlm.nih.gov/pubmed/26731269
http://dx.doi.org/10.1371/journal.pone.0146372
_version_ 1782408440584339456
author Cauwelaert, Natasha Dubois
Desbien, Anthony L.
Hudson, Thomas E.
Pine, Samuel O.
Reed, Steven G.
Coler, Rhea N.
Orr, Mark T.
author_facet Cauwelaert, Natasha Dubois
Desbien, Anthony L.
Hudson, Thomas E.
Pine, Samuel O.
Reed, Steven G.
Coler, Rhea N.
Orr, Mark T.
author_sort Cauwelaert, Natasha Dubois
collection PubMed
description The Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant formulated in a stable emulsion (GLA-SE) promotes strong T(H)1 and balanced IgG1/IgG2 responses to protein vaccine antigens. This enhanced immunity is sufficient to provide protection against many diseases including tuberculosis and leishmaniasis. To better characterize the adjuvant action it is important to understand how the different cytokines and transcription factors contribute to the initiation of immunity. In the present study using T-bet(-/-) and IL-12(-/-) mice and a blocking anti-IFNαR1 monoclonal antibody, we define mechanisms of adjuvant activity of GLA-SE. In accordance with previous studies of TLR4 agonist based adjuvants, we found that T(H)1 induction via GLA-SE was completely dependent upon T-bet, a key transcription factor for IFNγ production and T(H)1 differentiation. Consistent with this, deficiency of IL-12, a cytokine canonical to T(H)1 induction, ablated T(H)1 induction via GLA-SE. Finally we demonstrate that the innate immune response to GLA-SE, including rapid IFNγ production by memory CD8+ T cells and NK cells, was contingent on type I interferon, a cytokine group whose association with T(H)1 induction is contextual, and that they contributed to the adjuvant activity of GLA-SE.
format Online
Article
Text
id pubmed-4701231
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-47012312016-01-15 The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction Cauwelaert, Natasha Dubois Desbien, Anthony L. Hudson, Thomas E. Pine, Samuel O. Reed, Steven G. Coler, Rhea N. Orr, Mark T. PLoS One Research Article The Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant formulated in a stable emulsion (GLA-SE) promotes strong T(H)1 and balanced IgG1/IgG2 responses to protein vaccine antigens. This enhanced immunity is sufficient to provide protection against many diseases including tuberculosis and leishmaniasis. To better characterize the adjuvant action it is important to understand how the different cytokines and transcription factors contribute to the initiation of immunity. In the present study using T-bet(-/-) and IL-12(-/-) mice and a blocking anti-IFNαR1 monoclonal antibody, we define mechanisms of adjuvant activity of GLA-SE. In accordance with previous studies of TLR4 agonist based adjuvants, we found that T(H)1 induction via GLA-SE was completely dependent upon T-bet, a key transcription factor for IFNγ production and T(H)1 differentiation. Consistent with this, deficiency of IL-12, a cytokine canonical to T(H)1 induction, ablated T(H)1 induction via GLA-SE. Finally we demonstrate that the innate immune response to GLA-SE, including rapid IFNγ production by memory CD8+ T cells and NK cells, was contingent on type I interferon, a cytokine group whose association with T(H)1 induction is contextual, and that they contributed to the adjuvant activity of GLA-SE. Public Library of Science 2016-01-05 /pmc/articles/PMC4701231/ /pubmed/26731269 http://dx.doi.org/10.1371/journal.pone.0146372 Text en © 2016 Cauwelaert et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
spellingShingle Research Article
Cauwelaert, Natasha Dubois
Desbien, Anthony L.
Hudson, Thomas E.
Pine, Samuel O.
Reed, Steven G.
Coler, Rhea N.
Orr, Mark T.
The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
title The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
title_full The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
title_fullStr The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
title_full_unstemmed The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
title_short The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for T(H)1 Induction
title_sort tlr4 agonist vaccine adjuvant, gla-se, requires canonical and atypical mechanisms of action for t(h)1 induction
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701231/
https://www.ncbi.nlm.nih.gov/pubmed/26731269
http://dx.doi.org/10.1371/journal.pone.0146372
work_keys_str_mv AT cauwelaertnatashadubois thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction
AT desbienanthonyl thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction
AT hudsonthomase thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction
AT pinesamuelo thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction
AT reedsteveng thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction
AT colerrhean thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction
AT orrmarkt thetlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction
AT cauwelaertnatashadubois tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction
AT desbienanthonyl tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction
AT hudsonthomase tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction
AT pinesamuelo tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction
AT reedsteveng tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction
AT colerrhean tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction
AT orrmarkt tlr4agonistvaccineadjuvantglaserequirescanonicalandatypicalmechanismsofactionforth1induction